Are recovery peptides banned in sport?

Short answer: yes. The two recovery peptides lifters and injured athletes talk about most, BPC-157 and TB-500, are both on the World Anti-Doping Agency (WADA) Prohibited List, and both are banned at all times, in and out of competition. That rule applies to anyone tested under the WADA Code or a code built on it, from Olympic sport to many national federations and college programs. Here is where each peptide sits on the list, why the off-season offers no loophole, what the research on them actually shows, and how tested athletes approach soft-tissue recovery instead.

For the deeper look at what these compounds are studied for, see our guide to the evidence behind BPC-157 for tendon and soft-tissue recovery.

Are recovery peptides banned in sport?

Yes, the headline recovery peptides are prohibited for anyone bound by anti-doping rules. BPC-157 and TB-500 are both on the WADA Prohibited List, and using either one is an anti-doping rule violation regardless of when, why or how it was taken. The ban does not depend on the dose, the route (capsule or injection) or the reason (rehab rather than performance). It also does not depend on where the product came from: the list prohibits the substance, so a pharmacy label, a “research use only” label or a clinic setting makes no difference to a drug test. The pattern runs well beyond these two: PeptideAgent’s State of Peptides report for 2026 Q3 counts 43 of the 82 peptides it tracks (52%) as prohibited under the WADA list in force, and notes that the 2027 list, published September 21, 2026, still names BPC-157 under S0.

Are BPC-157 and TB-500 banned by WADA?

Yes. BPC-157 is prohibited in the S0 non-approved-substances class, the category the US Anti-Doping Agency describes as covering any substance “not approved for human clinical use by any global regulatory authority.” TB-500, the common name for a fragment of thymosin beta-4, was added by name as a prohibited growth factor: WADA’s rules state that “Thymosin-β4 and its derivatives, e.g. TB-500, were added as examples of prohibited growth factors under S2.3.” You can confirm both directly on the current WADA Prohibited List, which took effect on January 1, 2026.

The table below shows where the peptides most often marketed for recovery sit on the current list.

Blends follow the same logic. A “Wolverine” style product that combines BPC-157 and TB-500 contains two prohibited substances, not one.

Can an athlete use BPC-157 or TB-500 in the off-season?

No. “At all times” means out-of-competition use is a violation too, so there is no off-season window. Some substances, certain stimulants for example, are banned only in competition, which is why athletes sometimes assume they can use a compound during rehab and stop before the season. That reasoning does not apply here. Because S0 substances are banned both in and out of competition (USADA), stopping before a test window does not make earlier use legal under the rules.

Can a tested athlete get a Therapeutic Use Exemption for these peptides?

Not in any straightforward way. A Therapeutic Use Exemption (TUE) lets an athlete use a prohibited medicine they genuinely need, and it is built around recognized treatments. BPC-157 is prohibited precisely because no regulator has approved it for human use, and TB-500 has no approved indication either, so there is no established medical use to point to. USADA’s advice on the wider category is direct: athletes should “never use a product that is marketed for ‘research only’” (USADA). An athlete with a real injury is far better served asking their team physician which permitted options fit it.

What does the research on these recovery peptides actually show?

The evidence is real but early, and it is overwhelmingly from animals rather than people. A 2025 narrative review of BPC-157 for musculoskeletal healing found robust preclinical animal data alongside only three published human studies: a small uncontrolled series in knee pain, a pilot in interstitial cystitis, and a two-person intravenous safety study. The authors’ conclusion is that “BPC-157 should be considered investigational, and its use approached with caution.” The same review notes the peptide’s “growing popularity among athletes,” and dates the anti-doping turn to 2022, when WADA banned it under S0. TB-500 has even less human data; most of what is claimed for it comes from animal and cell studies of the full thymosin beta-4 protein, which our TB-500 research guide walks through.

So the honest summary for an athlete is two separate facts. The science is promising but unproven in people, and the sport rule is settled regardless of how the science turns out.

What do athletes and lifters say about these peptides?

Outside tested sport, BPC-157 and TB-500 are among the most talked-about recovery compounds on social media. Our snapshot of public posts (16 posts on X for each peptide, collected July 2026) found people describing them mainly as tissue-repair and injury-recovery aids, often used together, with accounts of returning to training after ligament and rotator cuff injuries. The same snapshot found a skeptical minority who said they were not convinced the TB-500 half of the stack did anything for them, and a sharp disagreement about safety. These are individual, unverified accounts, not evidence of effect, and none of them changes the anti-doping status. Our BPC-157 and TB-500 guide covers why the two are stacked and what is known about each.

What do tested athletes use for recovery instead?

They start with the injury and the medical staff, not with a specific molecule. For a drug-tested athlete, the WADA status is decisive on its own, so the accountable move is a rehab plan built from permitted options: supervised physical therapy, progressive loading, time, and approved medications or injections a team physician can discuss, checked against the current list. Our comparison of peptides and cortisone shots for injury covers the main established option and its trade-offs, including the fact that some corticosteroid routes are themselves restricted in competition, which is exactly why the current list should be checked before any treatment.

BPC-157 and TB-500 status: Not FDA-approved; sold by some telehealth providers as a compounded prescription. An FDA advisory committee reportedly voted in July 2026 to recommend allowing pharmacies to compound it; nothing has changed yet. How peptide status works.

Educational information only, not medical advice. Anti-doping statements are sourced to the WADA Prohibited List and USADA guidance linked above, current as of October 12, 2026. Always check the current list with your federation or anti-doping organization before using any substance.